Back to top
more

Novo Nordisk (NVO)

(Delayed Data from NYSE)

$111.94 USD

111.94
4,553,843

-0.01 (-0.01%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $111.97 +0.03 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Sweta Jaiswal headshot

Diabetes Devices Market on a Tear: 3 Stocks for Solid Returns

Consider these three stocks in the rapidly-growing diabetes devices market for grand returns.

    Orexigen Plummets on Filing of Chapter 11 of Bankruptcy Code

    Shares of Orexigen (OREX) have declined more than 75% of its value as the company announced that it is filing for bankruptcy.

      4 Buy-Ranked Large Cap Pharma Stocks to Boost Your Portfolio

      Though the large-cap pharma sector struggled a little after a strong start in 2018, it is largely expected to rebound as the year progresses.

        Pfizer Gets Mixed Feedback on Cancer Treatments From CHMP

        CHMP recommends in favor of two hematology medicines of Pfizer (PFE) while recommending against label expansion of kidney cancer drug, Sutent.

          Pharma Stock Roundup: AZN's Imfinzi Gets 2nd FDA Nod, MRK to Buy Australian Firm

          Key announcements this week included the FDA approval for a second indication of AstraZeneca's (AZN) Imfinzi and an acquisition offer by Merck (MRK).

            Eurozone Beats United States Again: 5 Hot Stock Picks

            5 Europe-based stocks to buy as the region scores decade-high growth rate in 2017.

              The Zacks Analyst Blog Highlights: Nordisk, TJX, Cigna, Regeneron and ArcelorMittal

              The Zacks Analyst Blog Highlights: Nordisk, TJX, Cigna, Regeneron and ArcelorMittal

                Allergan (AGN) to Report Q4 Earnings: What's in the Cards?

                While Allergan's (AGN) Q4 sales are likely to be driven by new as well as established products like Botox and international growth, generic competition for some key products will hurt sales.

                  Novo Nordisk (NVO) Misses Q4 Earnings Estimates, Sales Beat

                  Novo Nordisk's (NVO) top-line growth was backed by growth in new-generation insulin, Victoza, Saxenda, and haemophilia products.

                    Can Merck (MRK) Deliver a Positive Surprise in Q4 Earnings?

                    Merck's (MRK) new products like Keytruda and Bridion are likely to drive sales in the fourth quarter. However, headwinds remain in the form of genericization of key drugs and increasing competition.

                      Company News For Jan 30, 2018

                      Companies In The News are: LMT,DPS,CYOU,ABLYF,SNY,NVO

                        Sanofi on a Buyout Spree This Month, to Buy Ablynx for $4.8B

                        Sanofi (SNY) to acquire Ablynx for EUR 3.9 billion to expand its late stage pipeline and strengthen rare blood disorder growth platform.

                          Why Novo Nordisk (NVO) Might Surprise This Earnings Season

                          Novo Nordisk (NVO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

                            Arpita Dutt headshot

                            AbbVie (ABBV) Soars on Q4 Results: Key Takeaways from the Earnings Call

                            With AbbVie (ABBV) surpassing expectations in the fourth quarter, here's a look at a few important takeaways from the company's conference call.

                              AbbVie (ABBV) Q4 Earnings Beat, 2018 View Raised, Shares Up

                              AbbVie's (ABBV) Q4 earnings top estimates with revenues marginally beating the same. Sales of the company's lead marketed drug, Humira, also rise year over year.

                                Arpita Dutt headshot

                                Biotech M&A Off to a Strong Start in 2018: More Deals to Follow?

                                Does Celgene's (CELG) decision to acquire Juno signal the revival of biotech M&A activity after a slow 2017?

                                  The Zacks Analyst Blog Highlights: Johnson & Johnson, AbbVie, Amgen, Novo-Nordisk and Zoetis

                                  The Zacks Analyst Blog Highlights: Johnson & Johnson, AbbVie, Amgen, Novo-Nordisk and Zoetis

                                    Can These 4 Large-Cap Drug Stocks Deliver an Encore in '18?

                                    We present four large cap drug companies, which are expected to repeat their last year's industry beating performance in 2018.

                                      Novo Nordisk's (NVO) Hits 52-Week High: What's Driving It?

                                      Regulatory approvals of some key pipeline candidates along with the strong performance of products like Victoza have contributed to a rally in Novo Nordisk's (NVO) shares.

                                        Teva's Trisenox Gets FDA Approval as First-Line Treatment

                                        Teva Pharmaceutical (TEVA) receives approval from the FDA for label expansion of its leukemia drug, Trisenox, in first-line setting.

                                          Swarup Gupta headshot

                                          Foreign Stock Roundup: Infosys Beats; AstraZeneca's Asthma Drug Gets Approval in EU

                                          Global markets endured a volatile week, guided by opposing factors.

                                            Why is Novo Nordisk Stock Up More Than 50% in Past Year?

                                            We take a look at the factors that led to the rise in Novo Nordisk's (NVO) share price in the past year.

                                              Novo Nordisk's Ozempic Gets Canadian Approval for Diabetes

                                              Novo Nordisk (NVO) announced that Health Canada has approved Ozempic to improve glycemic control in adults with type II diabetes mellitus.

                                                Novo Nordisk Confirms Bid for Ablynx But Faces Rejection

                                                Novo Nordisk (NVO) confirmed its revised offer made on Dec 22, to acquire Ablynx NV for $3.1 billion.

                                                  3 Large-Cap Pharma Stocks to Watch Out for This New Year

                                                  We take a look at a few Large Cap drug stocks with a favorable combination of Zacks Rank and VGM Score. The stocks are poised to carry on their bull run this year too.